GSB Barbosa, NOS Câmara, FL Ledesma… - Frontiers in …, 2024 - frontiersin.org
In glomerulopathies, endothelial dysfunction and the presence of histological vascular lesions such as thrombotic microangiopathy, arteriolar hyalinosis, and arteriosclerosis are …
TM Hallam, SJ Sharp, A Andreadi, D Kavanagh - Immunobiology, 2023 - Elsevier
Complement factor I (FI) is the nexus for classical, lectin and alternative pathway complement regulation. FI is an 88kDa plasma protein that circulates in an inactive …
M Vivarelli, J Barratt, LH Beck Jr, F Fakhouri, DP Gale… - Kidney International, 2024 - Elsevier
Uncontrolled complement activation can cause or contribute to glomerular injury in multiple kidney diseases. While complement activation plays a causal role in atypical hemolytic …
Y Yang, K Cheng, G Xu - European Journal of Pharmacology, 2024 - Elsevier
Primary membranous nephropathy (PMN) is an immune-mediated glomerular disease. Rituximab (RTX) is recommended as a first-line immunosuppressive therapy and shows …
L Fu, J Ping, F Guo, J Song, M Luo… - Kidney and Blood Pressure …, 2023 - karger.com
Introduction: The disruption of podocyte structure and function are the main pathological mechanism of membranous nephropathy (MN). Phospholipases A2, Group XII B …
A Java, J Atkinson, Z Hu, N Pozzi - Blood, 2023 - ashpublications.org
Atypical hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy. Genetic variants in complement proteins are found in≈ 60% of patients. Of these patients,≈ 15 …
MI Akaeva, NL Kozlovskaya, LA Bobrova… - Terapevticheskii …, 2024 - ter-arkhiv.ru
Background. The spectrum of diseases characterized by the development of renal thrombotic microangiopathy (TMA) encompasses the malignant hypertension (MHT). TMA in …